Reversible and irreversible ototoxicity has been documented following the administration of various therapeutic agents. Reversible hearing loss is a known complication following the administration of quinine, salicylates and other nonsteroidal anti-inflammatory drugs, and erythromycin. We report a case of reversible hearing loss following OKT3 (murine monoclonal antibody CD3) administration. OKT3, a monoclonal antibody used as an immunosuppressant following cadaveric renal transplants, was associated with a transient sensorineural hearing loss that reversed following discontinuation of OKT3.
JungTTRheeCKLeeCSParkYSChoiDC. Ototoxicity of salicylate, non-steroidal antiinflammatory drugs, and quinine. Otolaryngol Clin North Am1993; 26: 791–810.
2.
WallachPMLoveSRFioricaJVHoffmanMSFlanneryMT. Erythromycin associated hearing loss in a patient with prior cis-platinum induced ototoxicity. J Fla Med Assoc1992; 79: 821–2.
ToddPBrogdenRN. Muromonab CD3: A review of its pharmacology and therapeutic potential. Drugs1989; 37: 871–99.
5.
Ortho Multicenter Transplant Study Group.A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med1985, 313: 337–42.
6.
ThistlethwaiteJRJrStuartJKMayesJT. Monitoring and complications of monoclonal therapy: Complications and monitoring of OKT3 therapy. Am J Kidney Dis1988; 9: 112–9.
7.
GastonRSDeierhoiMHPattersonT. OKT3 first dose reaction: Association with T cell subsets and cytokine release. Kidney Int1991; 39: 141–8.
8.
LefebvrePPVan De WaterTRWeberTRogisterBMoonenG. Growth factor interactions in cultures of dissociated adult acoustic ganglia: Neuronotrophic effects. Brain Res1991; 567: 306–12.
